Literature DB >> 22745181

Reversible heart failure: toxins, tachycardiomyopathy and mitochondrial abnormalities.

Paul D Morris1, Tim Robinson, Kevin S Channer.   

Abstract

Heart failure is usually a relentless condition associated with a poor prognosis. Triggered by a physiological insult, maladaptive neurohumoral processes result in an ever-spiralling deterioration of cardiovascular function. However, there are certain underlying conditions which are associated with a temporary reduction in contractile function leading to reversible heart failure. These conditions affect a relatively small number of patients when compared with heart failure secondary to inherited cardiomyopathies and ischaemic heart disease. There are two broad mechanisms responsible for reversible myocyte dysfunction: acute inflammatory activation in which cytokines depress myocyte function, and toxic effects in which there is impairment of intra-cellular energetics. In this review, we discuss reversible heart failure caused by toxic effects. These effects can be caused by drugs (prescribed and illicit) and by tachycardic arrhythmia (tachycardiomyopathy), and are caused by abnormalities of mitochondrial function and myocytic calcium processing. The underlying pathological mechanisms, clinical features and management options are discussed, illustrated by clinical case studies.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22745181     DOI: 10.1136/postgradmedj-2011-130698

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  4 in total

1.  Treatment of tachycardia: bradycardia syndrome in a patient with obstructive sleep apnoea.

Authors:  Jakub Lagan; Palaniappan Saravanan
Journal:  BMJ Case Rep       Date:  2015-04-01

2.  Persistent Atrial Fibrillation And Atrial Flutter Complicated By Tachycardiomyopathy Because Of Intermittent Conduction Through Accessory Pathway.

Authors:  L Valeri; A Coppolino; G Rossetti; A Vado; G Amoroso; G Bricco; A Battisti; L Correndo; S Dogliani; A Magliarditi; D Pancaldo; M De Benedictis; A Bassignana; B Doronzo
Journal:  J Atr Fibrillation       Date:  2016-04-30

Review 3.  Long-term management of end-stage heart failure.

Authors:  Marlena V Habal; A Reshad Garan
Journal:  Best Pract Res Clin Anaesthesiol       Date:  2017-07-18

4.  Atrial fibrillation in patients with systolic heart failure: pathophysiology mechanisms and management.

Authors:  Ioanna Koniari; Eleni Artopoulou; Dimitrios Velissaris; Nicholas Kounis; Grigorios Tsigkas
Journal:  J Geriatr Cardiol       Date:  2021-05-28       Impact factor: 3.327

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.